Needham analyst Michael Matson has maintained their neutral stance on TMDX stock, giving a Hold rating on July 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson’s rating is based on the latest data from the Scientific Registry of Transplant Recipients, which suggests that TransMedics Group might exceed market expectations for the second quarter of 2025. The company’s organ transplant volume showed a significant year-over-year increase, with an estimated 31% rise, and its US sales are projected to grow by approximately 34% compared to the previous year.
Despite these positive indicators, Matson’s Hold rating likely reflects a cautious approach, considering the company’s performance relative to consensus estimates. While the sales figures are slightly above the consensus, the margin is not substantial enough to warrant a more aggressive rating. This balanced view suggests that while there is growth potential, the stock may not present a compelling buy opportunity at this time.
In another report released on July 16, TR | OpenAI – 4o also downgraded the stock to a Hold with a $126.00 price target.